Debut Of Merck's Anacetrapib Debut Many Years Away, Despite Robust Phase III Data
Filing will wait until after 2015, pending results of a soon-to-launch CV outcomes study of the CETP inhibitor in 30,000 patients.
Filing will wait until after 2015, pending results of a soon-to-launch CV outcomes study of the CETP inhibitor in 30,000 patients.